Keytruda™ (pembrolizumab) has recently been approved for use in Europe for advanced head and neck cancer following a major Phase-III clinical trial led by the Institute of Cancer Research (London, UK). Researchers also showed it was possible to predict which patients would respond well to the immunotherapy.